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The p210 bcr-abl protein tyrosine kinase (PTK) appears to be directly responsible for the initial manifes-
tations of chronic myelogenous leukemia (CML). In contrast to the extensive characterization of the PTK and
its effects on cell function, relatively little is known about the nature of the protein tyrosine phosphatases
(PTPs) that may modulate p210 bcr-abl-induced signalling. In this study, we have demonstrated that expres-
sion of PTP1B is enhanced specifically in various cells expressing p210 bcr-abl, including a cell line derived
from a patient with CML. This effect on expression of PTP1B required the kinase activity of p210 bcr-abl and
occurred rapidly, concomitant with maximal activation of a temperature-sensitive mutant of the PTK. The
effect is apparently specific for PTP1B since, among several PTPs tested, we detected no change in the levels
of TCPTP, the closest relative of PTP1B. We have developed a strategy for identification of physiological
substrates of individual PTPs which utilizes substrate-trapping mutant forms of the enzymes that retain the
ability to bind to substrate but fail to catalyze efficient dephosphorylation. We have observed association
between a substrate-trapping mutant of PTP1B (PTP1B-D181A) and p210 bcr-abl, but not v-Abl, in a cellular
context. Consistent with the trapping data, we observed dephosphorylation of p210 bcr-abl, but not v-Abl, by
PTP1B in vivo. We have demonstrated that PTP1B inhibited binding of the adapter protein Grb2 to p210
bcr-abl and suppressed p210 bcr-abl-induced transcriptional activation that is dependent on Ras. These
results illustrate selectivity in the effects of PTPs in a cellular context and suggest that PTP1B may function
as a specific, negative regulator of p210 bcr-abl signalling in vivo.
Chronic myelogenous leukemia (CML) is a clonal myelo-
proliferative disorder of the pluripotential hematopoietic stem
cell characterized by the Philadelphia (Ph) chromosome. The
Ph chromosome is the result of a reciprocal translocation in
which the c-abl proto-oncogene on chromosome 9, encoding a
protein tyrosine kinase (PTK), transposes to a new position on
chromosome 22, in proximity to the breakpoint cluster region
(bcr). The juxtaposition of bcr and abl creates a novel fusion
gene that results in production of a chimeric protein termed
p210 bcr-abl. This hybrid bcr-abl oncoprotein has enhanced
PTK activity relative to c-Abl, which correlates with abnormal
patterns of tyrosine phosphorylation in cells from patients with
CML (reviewed in reference 29). bcr-abl can transform growth
factor-dependent lymphoid (9) and myeloid (23) cells in cul-
ture into factor-independent and tumorigenic cells. When the
bcr-abl gene is expressed in bone marrow cells through retro-
viral gene transfer in vitro followed by bone marrow transplan-
tation into sublethally irradiated mice, a myeloproliferative
CML-like syndrome occurs (10, 14, 27). These results strongly
suggest that p210 bcr-abl plays a fundamental role in the
pathogenesis of CML.
The state of tyrosine phosphorylation of proteins in vivo is
governed by the coordinated and competing actions of PTKs
and protein tyrosine phosphatases (PTPs). Current data sug-
gest that the Ph chromosome translocation that generates the
aberrantly activated p210 bcr-abl PTK fusion protein is the
initiating event in CML (29). Therefore an understanding of
the PTPs that have the ability to antagonize p210 bcr-abl func-
tion will provide a complementary perspective from which to
study and intervene in the disease.
The PTPs represent a large (;75 members identified to
date) and structurally diverse family of enzymes (reviewed in
reference 57) that have been implicated in the regulation of
cell growth and proliferation, differentiation, the cell cycle, and
cytoskeletal integrity, as well as the etiology and pathogenesis
of certain diseases. They have been identified in eukaryotes,
prokaryotes, viruses, and plants. It is now apparent that the
family of PTPs rivals that of the PTKs in structural diversity
and complexity. In addition, through the process of dephos-
phorylation, PTPs can either antagonize or potentiate PTK-
induced signaling events in vivo (57). Therefore, it is expected
that control over reversible phosphorylation in vivo will be
exerted at the level of both PTKs and PTPs.
The PTP domain is a 240-amino-acid segment that contains
the invariant residues necessary for phosphatase activity.
Within the PTP domain lies the signature motif (I/V)HCX
AGXXR(S/T)G that uniquely defines this enzyme family. The
cysteine residue within this sequence forms a thiophosphoen-
zyme intermediate necessary for catalysis. The members of the
PTP family may be distinguished on the basis of the noncata-
lytic segments that are fused to either the N or C terminus of
the catalytic domain. Like the PTK family, the family of PTPs
can be divided into two large classes, the transmembrane,
receptor-like PTPs and the nontransmembrane, intracellular
species. The receptor-like PTPs have diverse extracellular seg-
ments, a single membrane-spanning region, and (with a few
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exceptions) two tandemly repeated cytoplasmic PTP domains.
The nontransmembrane, intracellular PTPs contain a single
catalytic PTP domain flanked by various N- and C-terminal
motifs. These motifs are believed to have regulatory functions
including targeting to defined subcellular locations. For exam-
ple, PTP1B and the closely related, 48-kDa form of TCPTP
(74% identity in the catalytic domain) are targeted to the
cytoplasmic face of membranes of the endoplasmic reticulum
via a hydrophobic segment at their extreme C termini (16, 31);
TCPTP also exists as a spliced variant of 45 kDa that lacks the
hydrophobic segment and localizes to the nucleus (36, 53). A
second example is illustrated by the two SH2 (Src homology 2)
domain-containing PTPs, SHP-1 and SHP-2, which have been
shown to bind to specific phosphotyrosine residues in growth
factor and cytokine receptors and therefore are targeted to
signalling complexes at the plasma membrane (38).
Much research effort in the context of cellular signalling
events in CML has focused on p210 bcr-abl and the role of
aberrant tyrosine phosphorylation. Little is known about the
role of PTPs in CML. There have been preliminary reports of
uncharacterized PTPs with the ability to dephosphorylate p210
bcr-abl (39). In addition, the SH2 domain containing PTP,
SHP-2, which has been shown to function positively in medi-
ating tyrosine phosphorylation-dependent signalling events, is
phosphorylated on tyrosine residue(s), and forms a complex
with p210 bcr-abl in cells overexpressing the PTK (51); how-
ever, the significance of this association is unclear. To provide
further insight into the function of PTPs in the disease, we
initiated this study to ascertain which members of the PTP
family had the potential to regulate p210 bcr-abl function in
vivo. We have observed that PTP1B is upregulated specifically
in response to the expression of the p210 bcr-abl PTK in model
cell systems and in cell lines derived from a CML patient. We
present evidence that PTP1B recognizes p210 bcr-abl as a
substrate in a cellular context. Through the use of a mutant
form of PTP1B (PTP1B-D181A) that is catalytically impaired
but still binds to, and forms stable complexes with, its sub-
strates, we have captured p210 bcr-abl and PTP1B-D181A in a
physical complex in COS cells. This association, as well as
dephosphorylation of p210 bcr-abl by wild-type PTP1B, inhib-
ited binding of the Grb2 adapter molecule to the oncoprotein
PTK. Furthermore PTP1B and PTP1B-D181A, but not its
closest relative TCPTP or the cytoplasmic enzyme PTP-PEST,
suppressed p210 bcr-abl-induced transcriptional activation of
an AP-1/ets reporter that was dependent on the Ras pathway.
Our results suggest that PTP1B functions as a specific antag-
onist of signalling induced by p210 bcr-abl in vivo.
MATERIALS AND METHODS
Cell culture and preparation of lysates. Mo7 and Mo7p210 (p210 bcr-abl-
expressing Mo7) cells (34) were cultured in RPMI 1640 medium supplemented
with 20% fetal bovine serum. For Mo7 cells, the medium was further supple-
mented with granulocyte/macrophage colony-stimulating factor at 20 ng/ml.
Rat-1 fibroblasts, NIH 3T3 cells, and COS-1 cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine serum. BN1 and
BT1 cell pellets were kindly provided by B. Clarkson (Memorial Sloan Kettering
Cancer Center) (40). BaF3 cells expressing a temperature-sensitive (ts) mutant
of p210 bcr-abl (ts-p210 bcr-abl) were cultured as described by Jain et al. (25).
Stable Rat-1 fibroblasts expressing p210 bcr-abl, v-Abl, and v-Myc (Rat-1p210,
Rat-1v-Abl, and Rat-1v-Myc cells) were created as described elsewhere (41). In
all cases, cells were lysed in buffer comprising 50 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 1% (vol/vol) Triton X-100, 10% glycerol, 1 mM EDTA, 10 mg of leupeptin
per ml, 10 mg of aprotinin per ml, 1 mM benzamidine, and 1 mM phenylmeth-
ylsulfonyl fluoride.
Immunoblotting and antibodies. Protein concentrations were determined by
the Bradford method (3), using bovine serum albumin as the standard. Mono-
clonal antibodies FG6, against PTP1B, and CF4, against TCPTP, were provided
by David Hill (Calbiochem Oncogene Research Products, Cambridge, Mass.).
Anti-Abl antibodies (21-63 and Pex 5) are described in reference 41. Anti-PTP-
PEST polyclonal antibody is described in reference 17. The antiphosphotyrosine
(anti-pTyr) monoclonal antibody 4G10 was from Upstate Biotechnology Inc.
(Lake Placid, N.Y.). Monoclonal antibodies to SHP-2 and Grb2 were from
Transduction Laboratories (Lexington, Ky.). Polyclonal anti-PTP1B was kindly
provided by Ben Neel (Harvard Medical School). For immunoblotting, antigen-
bound antibody was detected with horseradish peroxidase-conjugated anti-
mouse or anti-rabbit secondary antibody and then visualized with enhanced
chemiluminescence (ECL; Amersham).
Immunoprecipitation and substrate trapping. COS-1 cells were transfected by
standard calcium phosphate precipitation. Vectors pSRaMSVtkneo and pSRa,
expressing the various PTKs and PTK mutants, are described in reference 41.
The generation of the PTP1B substrate-trapping mutant is described in reference
15. For immunoprecipitation, antibodies (Pex 5 and preimmune antiserum) were
coupled to protein A-Sepharose and incubated at 4°C for 90 min with lysates that
were precleared with IgGSorb (Enzyme Centre), followed by five washes of the
immunoprecipitates with lysis buffer. For substrate trapping in vivo, following
transient expression of mutant PTPs, COS-1 cells were lysed in lysis buffer
lacking sodium vanadate and the lysates were precleared by addition of IgG Sorb
reconstituted in lysis buffer, rocked at 4°C for 1 h, and then centrifuged at
15,000 3 g (4°C) for 5 min. Precleared lysate was added to a fresh tube contain-
ing 30 ml of glutathione-Sepharose beads (resuspended 1:1 in phosphate-buff-
ered saline [PBS]) or 30 ml of protein A beads (resuspended 1:1 in PBS). After
rocking at 4°C for 90 min, complexes were collected by centrifugation for 10 s at
1,000 3 g, the supernatant was discarded, and the beads were washed five times
in lysis buffer. For substrate trapping in vitro, glutathione S-transferase (GST)
fusion proteins (GST-PTP1B and GST–PTP1B-D181A, described by Flint et al.
[15]) were expressed in Escherichia coli, purified to homogeneity, and bound to
glutathione-Sepharose. Mo7p210 cells were lysed in the presence or absence of
the PTP inhibitor sodium vanadate (1 mM), and 200 mg of lysate was incubated
with the affinity matrix (GST–PTP1B-D181A) for 90 min at 4°C. Beads were
collected by low-speed (1,000 3 g) centrifugation for 10 s and washed five times
with wash buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.1% [vol/vol] Triton
X-100, 10% glycerol, 1 mM EDTA, 10 mg of leupeptin per ml, 10 mg of aprotinin
per ml, 1 mM benzamidine, 1 mM phenylmethylsulfonyl fluoride).
Dephosphorylation in vivo. COS-1 cells were cotransfected with 10 mg of
pSRap210 together with 15 mg of pMT2, pMT2PTP1B, or pMT2TCPTP. In
another set of experiments, 10 mg of either pSRap210, pSRap210Y177F, or
pSRav-abl was cotransfected with 15 mg of pMT2PTP1B or pMT2 vector con-
trol. After 48 h, cells were washed twice with PBS and then immediately lysed in
Laemmli sample buffer and heated to 90°C for 5 min. Equal volumes of lysate
were resolved by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophore-
sis (PAGE) and transferred to nitrocellulose membranes. The membrane was
incubated with an anti-Abl antibody, to control for equal protein loading, and
then stripped and reblotted with anti-pTyr to determine the extent of dephos-
phorylation.
Northern analysis. Total RNA (20 mg) was extracted from Mo7 and Mo7/p210
cells lines by the RNAzol method (Tel-Test, Inc.). After electrophoresis on a
formaldehyde-agarose (1%) gel, the RNA was transferred to GeneScreen mem-
brane. After UV cross-linking, the blot was hybridized with a full-length cDNA
fragment of PTP1B in hybridization solution (0.5 M Na2HPO4, 7% SDS, and 1
mM EDTA) at 65°C for 12 h. The PTP1B and TCPTP probe were labeled with
[a-32P]dCTP to a specific activity of 108 cpm/mg of DNA and used at 106 cpm/ml
following heat denaturation. Finally, the blot was washed four times in 1 mM
EDTA–1% SDS–40 mM Na2HPO4 at 65°C and subjected to autoradiography.
The blot was stripped by boiling the membrane in hybridization solution, washed
extensively at 65°C with the same solution, and then reprobed with full-length
TCPTP cDNA, which was used as an internal control. The agarose gel was
stained using ethidium bromide, prior to transfer, to visualize RNA integrity.
PTP assay. Precleared lysates (60 mg) from Rat-1 and Rat-1p210 cells were
incubated with either monoclonal antibody FG6 (anti-PTP1B) or a nonspecific
monoclonal antibody IgG coupled to protein A-Sepharose. After rocking at 4°C
for 2 h, immune complexes were collected by centrifugation for 15 s at 1,000 3
g and the supernatants were assayed for PTP activity (54). Immunodepleted
supernatants (2 or 8 mg) were incubated with 32P-labeled pTyr reduced, carbox-
amidomethylated, and maleylated (RCM) lysozyme in a total volume of 60 ml of
assay buffer (25 mM imidazole HCl [pH 7.2], 1 mg of bovine serum albumin per
ml, 0.1% b-mercaptoethanol). The reaction was terminated by addition of 290 ml
of 10% suspension of Norit A charcoal in 0.9 M HCl–90 mM Na4P2O7–2 mM
NaH2PO4. Samples were centrifuged at 15,000 3 g for 10 min, and 250 ml of
supernatant was counted in scintillant to measure release of 32Pi. Immunoblot
analysis of the immunodepleted lysates were carried out with an anti-PTP1B
antibody (FG6).
Transcriptional activation assay (CAT assay). NIH 3T3 cells were transfected
by standard calcium phosphate precipitation with 1 mg of pB4X-CAT reporter
plasmid and 2 mg of pC3LACZ reporter plasmid together with 0.5 mg of
pSRaMSVtkneo expressing either v-Abl or p210 bcr-abl in the presence or
absence of 5 mg of pMT2 expressing PTP1B, PTP1B-D181A, PTP-PEST, PTP-
PEST-D191A, or TCPTP. After 48 h, cells were harvested, washed twice with
PBS, and lysed in 400 ml of 13 reporter lysis buffer (Promega). Cell debris was
removed by centrifugation at 12,000 3 g for 5 min, and the resulting supernatants
were assayed for chloramphenicol acetyltransferase (CAT) and b-galactosidase
activities. b-Galactosidase activity was determined by incubating 0.15 ml of cell
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lysate with 0.15 ml of b-galactosidase reaction buffer (120 mM Na2HPO4, 80 mM
NaH2PO4, 2 mM MgCl2, 100 mM b-mercaptoethanol, 1.33 mg of o-b-D-thioga-
lactopyranoside per ml) at 37°C until a faint yellow color appeared. Reactions
were stopped by the addition of 1.0 M sodium carbonate, and spectrophotomet-
ric readings were taken at 420 nm. CAT assays were normalized for transfection
efficiency by reference to b-galactosidase activity measurements. CAT activity
was determined by incubating 0.1 mCi of [14C]chloramphenicol (NEN) and 0.44
mM acetyl coenzyme A in 250 mM Tris-HCl (pH 7.8) in a final reaction volume
of 100 ml for 45 min at 37°C. The reaction was then terminated by extraction with
ethyl acetate and subjected to thin-layer chromatography on silica gel plates,
using 95% chloroform–5% methanol (vol/vol) as the solvent.
RESULTS
The level of PTP1B is enhanced in p210 bcr-abl-expressing
cell lines. To examine whether expression of p210 bcr-abl ex-
erted an effect on the expression of members of the PTP
family, we examined, by immunoblotting, the levels of various
intracellular PTPs in the human myeloid cell line Mo7 and in
Mo7p210 cells (49). Strikingly, expression of only one of the
enzymes tested, PTP1B, was enhanced two- to threefold in
Mo7p210 compared to Mo7 cell lysates (Fig. 1A, top). In
contrast, no change was observed in the levels of TCPTP, the
phosphatase most closely related to PTP1B (74% identity in
the catalytic domain) (Fig. 1B, top). We also observed a cor-
responding increase in PTP1B mRNA levels in Mo7p210 com-
pared to Mo7 cells (Fig. 1C). The increased steady-state level
of PTP1B appears to be attributable to the increase in mRNA
levels since the protein half-life appeared unchanged. The in-
crease in PTP1B was also induced in Rat-1 fibroblasts express-
ing p210 bcr-abl. In these cells, we observed a three- to four-
fold increase in PTP1B levels that was not detected in cells
transformed by v-Abl or v-Myc (Fig. 1A, middle). As in the
Mo7 cells, the level of TCPTP was not altered as a conse-
quence of p210 bcr-abl expression in Rat-1 cells (Fig. 1B,
middle). To test whether the increase in PTP1B is observed
clinically, we blotted lysates from Ph1 and Ph2 B-lymphoid
cell lines derived from a CML patient. Consistent with other
p210 bcr-abl-expressing cell lines, there was an increase in
PTP1B protein in the Ph1 (BT1) compared to the Ph2 (BN1)
cell line, in this case a difference of ;2-fold (Fig. 1A, bottom).
Once again, there was no change in TCPTP protein expression
between the two cell lines (Fig. 1B, bottom).
Increased PTP activity in Rat-1p210 cells correlates with the
increase in PTP1B protein. Comparison of total PTP activities
in Rat-1 and Rat-1p210 cells revealed an increase of ;2.5-fold
in activity in the Rat-1p210 cells (Fig. 2A). The activity was
measured using [32P]pTyr RCM lysozyme as the substrate and
therefore reflects the combined activity of a variety of PTPs
present in the lysate. In view of the enhancement of PTP1B
protein levels observed in Rat-1p210 cells, we examined the
contribution of PTP1B to the increased activity by quantitative
immunodepletion of the enzyme from lysates. The activity at-
tributable to PTP1B was three- to fourfold higher in lysates of
Rat-1p210 than in lysates of control Rat-1 cells (Fig. 2B); this
correlated with the increase in PTP1B protein in Rat-1p210
cells (Fig. 1A, middle), suggesting that the intrinsic phospha-
FIG. 1. Expression of PTP1B but not TCPTP is enhanced in Mo7, Rat-1, and B-lymphoid cells expressing p210 bcr-abl. Shown are results of immunoblot analyses
of PTP1B (A), using monoclonal antibody FG6, and TCPTP (B), using monoclonal antibody CF4, visualized by ECL. (C) Enhancement of PTP1B mRNA following
expression of p210 bcr-abl in Mo7 cells. A Northern blot containing 20 mg of total RNA from Mo7 and Mo7p210 cells was probed with PTP1B cDNA and then stripped
and reprobed with TCPTP cDNA. Equal loading and integrity of the RNA samples were confirmed by ethidium bromide staining of the 28S and 18S rRNAs in the
gel before transfer to nitrocellulose.
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tase activity of PTP1B was not altered in p210 bcr-abl-express-
ing cells. Following immunodepletion of PTP1B, there was no
apparent difference in activity in lysates of cells in the presence
or absence of p210 bcr-abl expression, suggesting that the
increase in total PTP activity in lysates from Rat-1p210 cells
can be attributed almost exclusively to the increased expression
of PTP1B. Immunoblot analysis revealed that PTP1B protein
had been quantitatively immunodepleted from the cell lysates
(Fig. 2C). Similar results were observed in a comparison of
PTP activity in lysates of Mo7 and Mo7p210 cells (data not
shown).
The tyrosine kinase activity of p210 bcr-abl is essential for
the overexpression of PTP1B. To investigate whether the PTK
activity of p210 bcr-abl plays a role in the enhancement of
PTP1B levels, we generated stable Rat-1 fibroblasts expressing
a catalytically inactive mutant of p210 bcr-abl in which the
lysine residue in the ATP binding site was mutated to arginine
(K1172R). The kinase-deficient p210 bcr-abl protein was ex-
pressed at levels similar to those of the wild-type protein (Fig.
3C). Immunoblotting with an anti-pTyr antibody confirmed
that the p210 bcr-abl-K1172R mutant is inactive as a PTK (Fig.
3B). Immunoblot analyses of PTP1B from lysates of Rat-1p210
and Rat-1p210 K1172R cells revealed that PTP1B was in-
creased only in the cells expressing the catalytically active PTK
(Fig. 3A). These data implicate the PTK activity of p210 bcr-
abl as essential for the upregulation of PTP1B levels.
The increase in PTP1B levels is induced rapidly following
activation of a ts mutant of p210 bcr-abl. To investigate
whether the increase in PTP1B expression that occurs follow-
ing activation of the PTK is a rapid or a long-term, adaptive
response, we have used BaF3 cells containing the ts-p210 bcr-
FIG. 2. Increased PTP activity in Rat-1p210 compared to Rat-1 cells corre-
lates with the increase in PTP1B protein. (A) PTP activity from equal quantities
of lysate protein (2 and 8 mg) from Rat-1 and Rat-1p210 cells was determined by
using RCM lysozyme as the substrate, before and after quantitative immu-
nodepletion of PTP1B. (B) Activity due specifically to PTP1B was determined by
subtracting the activity in lysates following immunodepletion by antibodies to
PTP1B from the total activity. The PTP activity is presented as the mean 6
standard error of four independent assays. PTP1B activity in Rat-1p210 cells is
FIG. 3. The intrinsic tyrosine kinase activity of p210 bcr-abl is required for
the overexpression of PTP1B. Equal quantities of lysate protein from Rat-1v-
Abl, Rat-1p210, and Rat-1p210-K1172R cells were prepared and immunoblotted
with antibodies to PTP1B (A), pTyr (B), and Abl (C). Immunoblots were visu-
alized by ECL.
expressed as fold increase in the activity observed in Rat-1 cells, with the activity
in Rat-1 cells was set at a value of 1. (C) Immunoblot analysis of the quantitative
immunodepletion of PTP1B from lysates of Rat-1 and Rat-1p210 cells used in
the PTP activity assay. Total lysate (2 or 8 mg) was immunodepleted with
anti-PTP1B antibody or control nonspecific mouse IgG; the depleted lysate was
then subjected to immunoblot analysis using a monoclonal antibody (FG6) to
PTP1B and visualized by ECL.
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abl gene (25). Cells growing at the nonpermissive temperature
(39°C) were switched to the permissive temperature (33°C),
and lysates were prepared at various times up to 24 h. We
observed a gradual increase in both p210 bcr-abl expression
and overall tyrosine phosphorylation, reaching a maximum at
12 to 24 h after the shift in temperature. We also observed that
the increase in expression of PTP1B coincided with the period
of maximal activation of p210 bcr-abl (Fig. 4). There was no
detectable difference in SHP-2 expression following p210 bcr-
abl activation (Fig. 4, bottom). These data make the important
point that the increase in PTP1B levels is a relatively rapid
response to the activation of p210 bcr-abl, suggesting that this
may reflect a compensatory change to the presence of the
oncoprotein PTK rather than a long-term adaptive response of
the cell. This finding suggests either that PTP1B may play a
positive, permissive role in p210 bcr-abl induced signalling or
that the induction of PTP1B may reflect a feedback mechanism
to curtail the effects of the PTK.
Association of p210 bcr-abl with a substrate-trapping mu-
tant of PTP1B. With the resolution of the structure of PTP1B,
alone and in a complex with a phosphotyrosyl peptide substrate
(2, 26), several residues that are important for substrate rec-
ognition and catalysis have been identified. Based on these
observations, a series of mutations within the catalytic domain
of PTP1B were created and tested for substrate recognition
(15). In the past, we and others have shown that mutant PTPs
in which the catalytically essential, nucleophilic cysteine, from
the signature motif, has been mutated to serine or alanine
retain the ability to bind substrates in vitro and in some cases
in vivo (22, 26, 35, 48, 50). However, not all such mutants can
bind to physiological substrates in vivo. We have generated an
additional substrate-trapping mutant in which the catalytically
essential, invariant aspartate (D181 in PTP1B), which func-
tions as a general acid in protonating the tyrosyl leaving group
of the substrate, has been changed to alanine. In this mutant,
the affinity for substrate (Km) is maintained but catalytic effi-
ciency (Vmax) is severely impaired. The properties of these
substrate-trapping mutants are described elsewhere (15, 17).
Use of the PTP1B-D181A mutant has provided evidence
suggesting that p210 bcr-abl is a physiological substrate of
PTP1B. Using an affinity matrix that comprises an immobilized
GST fusion protein of PTP1B-D181A, we were able to precip-
itate p210 bcr-abl from lysates of Mo7p210 cells (Fig. 5). To
confirm that the interaction between p210 bcr-abl and PTP1B-
D181A involved the catalytic center of the phosphatase, we
tested the effects of the PTP inhibitor sodium vanadate. So-
dium vanadate (a transition-state analog of phosphate) has
been shown to inhibit PTP activity by covalently modifying the
essential, nucleophilic cysteine residue at the active site (13,
24). We observed that the interaction between p210 bcr-abl
and GST–PTP1B-D181A was inhibited in the presence of 1
mM sodium vanadate (Fig. 5).
FIG. 4. PTP1B levels are enhanced rapidly following induction of p210 bcr-
abl. BaF3 cells expressing a ts mutant of p210 bcr-abl were maintained at the
nonpermissive temperature (39°C) for 18 h prior to a shift to the permissive
temperature (33°C). At various time points (1, 4, 12, and 24 h), the levels of
expression of p210 bcr-abl, PTP1B, and SHP-2 and the pTyr content of the cells
were assessed by immunoblotting. For each time point, ;106 cells were centri-
fuged, washed with PBS, and then quick-frozen in an ethanol-dry ice bath. The
cell pellets were lysed, and equal quantities of lysate protein was subjected to
SDS-PAGE. Immunoblotting was performed with monoclonal antibodies to Abl,
pTyr (pY), and PTP1B, as indicated. The PTP1B blot was stripped and reprobed
with an antibody to SHP-2 (bottom). The zero time point represents lysate from
cells grown at the nonpermissive temperature. Molecular size standards (in
kilodaltons) are indicated to the right.
FIG. 5. Association of p210 bcr-abl with a substrate-trapping mutant of
PTP1B in vitro. Mo7p210 cells were lysed in the presence or absence of the PTP
inhibitor sodium vanadate (1 mM), and 100 mg of lysate was incubated with an
affinity matrix comprising GST–PTP1B-D181A immobilized on glutathionine-
Sepharose for 90 min at 4°C. The affinity matrix was pretreated with 1 mM
sodium vanadate before incubation. Beads were collected by low-speed (1,000 3
g) centrifugation for 10 s and washed five times with wash buffer. Samples were
analyzed by immunoblotting with anti-Abl (A) and anti-pTyr (B) antibodies.
Immunoblots were visualized by ECL. The first lane in each panel illustrates an
immunoblot of 25 mg of Mo7p210 lysate. Molecular size standards (in kilodal-
tons) are indicated to the left.
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To determine whether PTP1B-D181A forms a physical com-
plex with p210 bcr-abl in intact cells, we examined whether the
two proteins coprecipitated following transient cotransfection.
We prepared lysates from COS cells coexpressing p210 bcr-abl
and GST-PTP1B or GST–PTP1B-D181A and isolated the PTP
fusion proteins on glutathione-Sepharose. We observed ;10%
of p210 bcr-abl in association with PTP1B-D181A, whereas
wild-type enzyme failed to precipitate p210 bcr-abl (Fig. 6).
PTP1B-D181A selectively binds tyrosine-phosphorylated
p210 bcr-abl but not v-Abl in vivo. To characterize further the
interaction between p210 bcr-abl and PTP1B-D181A, we again
used a cotransfection assay in COS cells. GST–PTP1B-D181A
was coexpressed with either p210 bcr-abl, v-Abl, or p210 bcr-
abl-Y177F, a mutant in which the autophosphorylation site
responsible for binding Grb2 was changed to Phe. The cells
were lysed, and GST–PTP1B-D181A was precipitated by using
glutathione-Sepharose. We observed that both p210 bcr-abl
and p210 bcr-abl-Y177F were recovered in a stable complex
with the trapping mutant form of PTP1B (Fig. 7). Specificity in
the interaction between PTP1B and tyrosine-phosphorylated
p210 bcr-abl is illustrated by the fact that when v-Abl and
GST–PTP1B-D181A were coexpressed in the same system, no
association between the PTK and the mutant PTP was ob-
served, despite the fact that v-Abl was expressed abundantly
and was phosphorylated on tyrosyl residues (Fig. 7). Unlike
autophosphorylated p210 bcr-abl, endogenous c-Abl, which
was not detectably tyrosine phosphorylated, was not recog-
nized by the trapping mutant of PTP1B. The 190-kDa tyrosine-
phosphorylated protein recognized by the mutant PTP is the
epidermal growth factor receptor (EGF-R), as confirmed by
immunoblotting with an anti-EGF-R antibody (15) (data not
shown).
PTP1B dephosphorylates p210 bcr-abl in a cellular context.
To determine whether p210 bcr-abl is a substrate of wild-type
PTP1B in a cellular context, we used COS cells transiently
expressing cDNA for p210 bcr-abl together with cDNA for
either PTP1B or the 48-kDa form of TCPTP. Two days post-
transfection, cells were lysed directly in Laemmli sample
buffer, thus preventing any dephosphorylation postlysis in
vitro. Immunoblotting the lysates with an anti-Abl monoclonal
antibody revealed that p210 bcr-abl is expressed (Fig. 8A).
PTP1B and TCPTP, which display comparable specific activi-
ties in assays in vitro (55, 62), were overexpressed in the p210
bcr-abl transfectants (Fig. 8C and D). When we compared
phosphotyrosine levels in p210 bcr-abl, using an anti-pTyr
monoclonal antibody, we found a significant reduction in the
levels of phosphotyrosine in p210 bcr-abl when cotransfected
with PTP1B, but the effects were much less pronounced with
TCPTP (Fig. 8B). This result confirms that in a cellular con-
text, p210 bcr-abl PTK is a better substrate for PTP1B than
TCPTP. Interestingly, PTP1B efficiently dephosphorylated
p210 bcr-abl as well as p210 bcr-abl-Y177F, but not v-Abl, even
though v-Abl is tyrosine phosphorylated (Fig. 9). These results
are consistent with the trapping mutant data, in which PTP1B-
D181A associates with p210 bcr-abl and p210 bcr-abl-Y177F
but not with v-Abl (Fig. 7).
FIG. 6. PTP1B-D181A physically associates with p210 bcr-abl in vivo. COS-1
cells were cotransfected with 10 mg of pSRaMSVtkneop210 plasmid DNA to-
gether with 10 mg of pMT2 expression plasmid for GST-PTP1B, wild type or
D181A mutant. (A) Lanes: L, immunoblot of cell lysate (25 mg) following
cotransfection; G, immunoblot of the glutathione-Sepharose precipitates from
200 mg of lysate. (B) Lanes C and G, 10 mg of the lysates of untransfected COS
cells (C) or COS cells coexpressing GST-PTP1B fusion proteins together with
p210 bcr-abl (G). Samples were subjected to immunoblot analysis with anti-Abl
(A) and anti-PTP1B (B) antibodies and visualized by ECL.
FIG. 7. Tyrosine-phosphorylated p210 bcr-abl, but not v-Abl, is selectively
recognized by PTP1B-D181A in vivo. COS-1 cells were cotransfected with 10 mg
of plasmid DNA pSRaMSVtkneop210, pSRaMSVtkneop210-Y177F, or
pSRaMSVtkneov-abl together with 10 mg of plasmid pMT2 GST-PTP1B-
D181A. Lanes: L, immunoblot of cell lysate (25 mg) following cotransfection; G,
immunoblot of the glutathione-Sepharose precipitates from 250 mg of lysate; A,
protein A precipitates from 250 mg of lysate. Samples were immunoblotted with
anti-Abl, anti-pTyr (anti-pY), and anti-PTP1B antibodies and visualized by ECL.
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Coexpression of p210 bcr-abl with either PTP1B or PTP1B-
D181A disrupted the association of endogenous Grb2 with the
PTK. These data strongly suggest that PTP1B recognizes p210
bcr-abl as a substrate. Therefore, we tested the effects of
PTP1B on signalling events triggered by the PTK. Rat-1p210
cells grow in soft agar and form tumors in nude mice (32).
Transformation of fibroblasts by p210 bcr-abl is dependent on
phosphorylation of the tyrosine residue at position 177 (which
is located in the consensus Grb2 binding site YXNX) within
the bcr region. This residue becomes autophosphorylated,
binds to the SH2 domain of the adapter protein Grb2, and
links bcr-abl to the Ras signalling cascade. Mutation of ty-
rosine 177 to phenylalanine abolishes Grb2 binding and Ras
activation and reduces the ability of p210 bcr-abl to transform
Rat-1 fibroblasts (41). In addition, expression of Grb2 SH2
domain deletion mutants in p210 bcr-abl-transformed cells in-
hibits bcr-abl-induced activation of Ras and reverses the trans-
formed phenotype (19). To address the effect of PTP1B on
p210 bcr-abl signalling, we determined whether the interaction
with the mutant PTP or dephosphorylation by wild-type en-
zyme affected the ability of the PTK to associate with en-
dogenous Grb2. Using transient cotransfection in COS cells
followed by immunoprecipitation from cell lysates with an anti-
Abl antibody, we observed that in the presence of either
PTP1B or PTP1B-D181A, the association of Grb2 and p210
bcr-abl was reduced by ;90% (Fig. 10A). Equal quantities of
wild-type and mutant p210 bcr-abl were expressed in each of
these assays (Fig. 10B).
PTP1B selectively antagonizes p210 bcr-abl-induced, Ras-
dependent induction of expression of an AP-1/ets reporter
construct. A correlation exists between the ability of oncogenic
PTKs to activate transcription from a Ras-responsive (AP-1/
ets) element and their ability to transform cells (29, 41). To
determine whether disruption of the Grb2–p210 bcr-abl inter-
action by PTP1B and PTP1B-D181A (Fig. 10A) inhibited the
ability of p210 bcr-abl to activate a Ras-responsive element, we
used a transcriptional activation assay. We utilized a CAT
FIG. 9. PTP1B dephosphorylates tyrosine phosphorylated p210 bcr-abl but
not v-Abl in vivo. COS-1 cells were cotransfected with 10 mg of plasmid DNA for
pSRaMSVtkneop210, pSRaMSVtkneop210-Y177F, or pSRaMSVtkneov-abl
together with 10 mg of plasmid pMT2 or pMT2PTP1B. At 48 h posttransfection,
2 3 106 cells were washed once with PBS and then immediately lysed in Laemmli
sample buffer and heated at 95°C for 5 min. Equal quantities of lysate protein
were then separated by SDS-PAGE, transferred to nitrocellulose, and analyzed
by immunoblotting with an anti-pTyr antibody (bottom). The blot was stripped
and reprobed with an anti-Abl antibody (top). Blots were visualized by ECL.
FIG. 10. Expression of PTP1B and PTP1B-D181A disrupts the association of
endogenous Grb2 with p210 bcr-abl. COS-1 cells were cotransfected with 5 mg of
plasmid DNA pSRap210 or pSRap210Y177F together with 15 mg of plasmid
DNA pMT2, pMT2PTP1B, or pMT2PTP1B-D181A as indicated. Lanes L depict
cell lysate (25 mg) following cotransfections. Cell lysates (250 mg) were prepared
as described in the text, and p210 bcr-abl was immunoprecipitated with an
anti-Abl antibody, Pex 5 (lanes A); a preimmune anti-serum (lanes P) was
included as a control. Immunoprecipitates were resolved by SDS-PAGE, trans-
ferred to nitrocellulose, and immunoblotted with an antibody to Grb2 (A). (B)
Anti-Abl immunoblot of the immunoprecipitates from 50 mg of lysate, as a
control to illustrate constant levels of p210 bcr-abl. Immunoblots were visualized
by ECL.
FIG. 8. Preferential dephosphorylation of p210 bcr-abl by PTP1B, compared
to TCPTP, in a cellular context. COS-1 cells were transfected with 10 mg of
pSRap210 together with 15 mg of either pMT2 vector, pMT2-PTP1B, or pMT2-
TCPTP. At 48 h posttransfection, 2 3 106 cells were washed once with PBS and
then immediately lysed in Laemmli sample buffer and heated at 95°C for 5 min.
Equal quantities of lysate protein were then separated by SDS-PAGE, trans-
ferred to nitrocellulose, and analyzed by immunoblotting with anti-Abl, anti-
pTyr (anti-pY), anti-PTP1B, and anti-TCPTP antibodies and visualized by ECL.
Molecular size standards (in kilodaltons) are indicated on the left.
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reporter gene construct under the control of a b-globin pro-
moter containing four tandem Ras-responsive elements,
pB4X-CAT (47, 58). We observed ;75% suppression of p210
bcr-abl-induced Ras activation in NIH 3T3 cells cotransfected
with p210 bcr-abl and either wild-type or D181A mutant
PTP1B compared to p210 bcr-abl alone (Fig. 11A). In the same
assay, expression of PTP1B and PTP1B-D181A exerted mini-
mal effect upon v-Abl-induced transcriptional activation. Al-
though v-Abl has not been shown to bind directly to Grb2, it is
known that v-Abl activates Ras through other mechanisms,
most likely via phosphorylation of Shc and formation of Shc-
Grb2 complexes (43, 52, 56, 64). Thus, although v-Abl utilizes
the same signalling pathway downstream of Grb2, it is not
inhibited by PTP1B. This important control illustrates that the
effects of PTP1B are exerted upstream of Grb2, at the level of
p210 bcr-abl. Interestingly, expression of neither the closest
relative of PTP1B, TCPTP, nor wild-type PTP-PEST and the
substrate-trapping mutant PTP-PEST-D199A exerted a signif-
icant effect on p210 bcr-abl-induced transactivation of the Ras-
responsive element (Fig. 11A). The expression levels of the
various proteins involved in the CAT assay are shown in Fig.
11B. These data illustrate selectivity in the effects of PTP1B on
this p210 bcr-abl-induced signalling response.
DISCUSSION
One of the earliest events in the development of CML is the
generation of the Ph chromosome, the translocation that re-
sults in production of the p210 bcr-abl fusion protein. The
various aspects of the progression of CML suggest that the
p210 bcr-abl PTK oncoprotein aberrantly regulates multiple
signalling pathways involved in proliferation, differentiation,
and apoptosis (7). Consequently, much research effort has
focussed on characterization of the effects of p210 bcr-abl on
cell signalling.
Expression of p210 bcr-abl leads to transformation of fibro-
blasts and hematopoietic cells and prevents apoptosis that is
normally triggered by cytokine deprivation of factor-depen-
dent cells (8). Various point mutant forms of p210 bcr-abl,
including a mutant in the site of autophosphorylation that
serves as a docking site for the adapter protein Grb2 (Y177F),
a mutant in the SH2 domain that is defective in interaction
with pTyr proteins (R552L), and a mutant in the major auto-
phosphorylation site in the catalytic domain (Y793F), have
been used to demonstrate that multiple signalling pathways
emanate from p210 bcr-abl (8). Further sites of tyrosine phos-
phorylation have been identified in p210 bcr-abl. Y283 is phos-
phorylated in vitro, and Y360 is phosphorylated in vitro and in
vivo; however, the implications for PTK function are unclear
(30). Additional substrates have been identified, including the
GTPase-activating protein (GAP)-associated p62 protein
p62dok (5, 61), p95vav, which contains SH2 and SH3 domains
and may possess GDP-GTP exchange factor activity (33), and
the proto-oncoprotein p120cbl, which can serve as a docking
protein (12, 44, 45). In addition to p210 bcr-abl, p120cbl copre-
cipitated the p85 subunit of phosphatidylinositol 39-kinase,
suggesting potential links to phospholipid-dependent signal-
ling pathways (45), and certain focal adhesion proteins (44).
There are data to suggest that members of the Src family of
PTKs become activated in p210 bcr-abl-expressing cells (11),
thus raising the possibility that additional PTKs contribute to
the aberrant tyrosine phosphorylation patterns observed in
CML. Clearly, the situation is complex and much remains to be
discovered about the tyrosine phosphorylation-dependent signal-
ling events that contribute to the CML phenotype.
Whereas much attention has focused on p210 bcr-abl and
FIG. 11. PTP1B antagonizes a Ras-dependent activation of transcription by
p210 bcr-abl but not v-Abl. (A) Transcriptional activation from a Ras-responsive
(AP-1/ets) promoter was performed essentially as described previously (41).
CAT activity was measured from NIH 3T3 cells transfected with plasmid pB4X-
CAT together with either plasmid vector p210 bcr-abl or v-Abl expression plas-
mids, in the presence or absence of various PTP expression plasmids. Percentage
conversion to acetylated forms was quantitated with a PhosphorImager. Data are
means 6 standard errors of four independent experiments; results from cells
expressing the reporter gene alone (vector) were assigned a value of 1. The various
PTPs alone did not alter basal CAT activity significantly. (B) Expression levels of the
various proteins involved in the CAT assay. A 50-mg amount of total lysate was used
to immunoblot for p210 bcr-abl and v-Abl. A 5-mg amount of total lysate was used
to detect PTP1B, TCPTP, and PTP-PEST. Antibodies to the various proteins are
described in the text.
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the role of aberrant tyrosine phosphorylation in CML, the
PTPs represent an underutilized resource for the study of this
oncoprotein PTK. It is clear that members of the PTP family
have the potential to exert a considerable influence on p210
bcr-abl function, acting at the level of either the PTK itself or
its downstream substrates. Our data indicate that a specific
PTP, PTP1B, can antagonize the ability of p210 bcr-abl to
signal in a cellular context.
PTP1B is the prototypical PTP. It comprises an N-terminal
catalytic domain fused to a C-terminal, regulatory segment (4,
6, 21, 55, 56). The extreme C-terminal 35 residues comprise a
hydrophobic segment that is both necessary and sufficient for
targeting the enzyme to the cytoplasmic face of membranes of
the endoplasmic reticulum (16), and as such, PTP1B will be
exposed to a substantial array of cellular phosphotyrosyl pro-
teins. However, information regarding the physiological func-
tion of PTP1B is limited at present. It has been shown to revert
partially the phenotype of v-Src-transformed 3T3 cells when
overexpressed up to 25-fold (60) and, again upon overexpres-
sion, to confer resistance to transformation by the Neu PTK
(63) and to inhibit signalling in response to interleukin-3 (18).
In addition, through the use of overexpression strategies and
inhibitory antibodies, PTP1B has been implicated in negative
regulation of signalling events triggered by the insulin receptor
(1, 28, 37). Generally, these observations have relied on strat-
egies involving overexpression of PTP1B, and thus it is unclear
whether these results reflect a physiological function of the
enzyme or whether there is specificity for PTP1B in these
effects.
Our observation that the levels of PTP1B were enhanced
rapidly and specifically as a consequence of expression of p210
bcr-abl suggests an important role for PTP1B in signalling
events induced by p210 bcr-abl, potentially acting either posi-
tively in a permissive function or negatively as an antagonist of
the PTK-induced signals. The increased expression of PTP1B
was observed in a variety of model cell systems for CML as well
as, more importantly, in Ph1 cell lines derived from a patient
with CML. Specificity is illustrated by the fact that although the
levels of PTP1B were increased following expression of p210
bcr-abl, we did not detect an increase in the level of TCPTP,
the closest relative of PTP1B. In addition, we did not detect
changes in the expression of SHP-2, which has been shown to
form a complex with p210 bcr-abl in cells overexpressing the
PTK (51). Furthermore, specificity in the response was also
evident from the perspective of the PTK, in that although
PTP1B was upregulated in response to p210 bcr-abl, in a man-
ner that was dependent on the catalytic activity of the PTK,
there was no change in the level of the phosphatase in Rat-1
fibroblasts expressing v-Abl, which has the same catalytic do-
main as p210 bcr-abl. In addition, PTP1B levels were not
altered in Rat-1 fibroblasts transformed by v-Myc, illustrating
that the change in PTP1B levels was not a general response to
cellular transformation.
Our study of PTP1B in the context of p210 bcr-abl-induced
signalling was predicated upon the observation that the level of
this PTP was increased specifically in response to expression of
this PTK oncoprotein. This observation is consistent with a
situation in which the cell may respond to expression of p210
bcr-abl by increasing the levels of a natural antagonist of the
PTK in an attempt to maintain a normal status of tyrosine
phosphorylation. This is reminiscent of compensatory changes
to an initial stimulus that have been observed in other systems.
For example, heterologous expression of the catalytic subunit
of protein kinase A in NIH 3T3 cells results in a compensatory
upregulation of expression of the endogenous regulatory sub-
unit (58). Interestingly, this is also consistent with the obser-
vation that upregulation of mRNA for PTP1B, LAR, PTPH1,
and PTPa was reported in response to heterologous overex-
pression of another PTK oncoprotein, Neu (59, 63). However,
in this latter case the effects on PTP protein levels and the
consequences for cellular signalling events have not been ad-
dressed.
In this study, we present data to illustrate that PTP1B can
function in a cellular context as a specific inhibitor of p210
bcr-abl-induced signalling events. Ras has been implicated
strongly in transformation by bcr-abl (46). It has been pro-
posed that a site of autophosphorylation in the bcr portion of
p210 bcr-abl (Y177) serves as a docking site for the adapter
protein Grb2 and functions to assemble the multiprotein com-
plex that triggers the Ras cascade (41, 42). In fact, dominant-
negative mutant forms of Grb2 have been shown to suppress
p210 bcr-abl-induced activation of Ras and to revert the trans-
formed phenotype of K562 cells and Rat-1 cells expressing
p210 bcr-abl, without inactivating its intrinsic PTK activity
(19). For transformation of hematopoietic bone marrow cells
or for tumor formation in vivo, alternative pathways to activa-
tion of Ras that involve another adapter protein, Shc, have also
been proposed (20). Using the AP-1/ets reporter construct to
measure the activation of the Ras cascade by p210 bcr-abl in a
cellular context, we have shown that PTP1B was capable of
antagonizing p210 bcr-abl-induced signalling. Specificity in the
response is reflected in the fact that PTP1B did not inhibit
transcriptional activation of the same reporter by v-Abl, sug-
gesting that Y177 in p210 bcr-abl is one of the targets for the
PTP. Furthermore, expression of TCPTP or PTP-PEST did
not affect p210 bcr-abl-induced signalling, as measured by this
transcriptional activation assay.
Signalling by p210 bcr-abl was also inhibited by a substrate-
trapping mutant of PTP1B, suggesting that a critical substrate
in the signalling pathway was being held in a complex with this
mutant and being rendered nonfunctional. As observed for the
active PTPs, this mutant of PTP1B did not affect induction of
the reporter gene by v-Abl and an equivalent mutant of PTP-
PEST did not inhibit signalling by p210 bcr-abl. This substrate-
trapping mutant of PTP1B contains a substitution of alanine
for the invariant aspartate (Asp181) that serves as a general
acid in protonating the tyrosyl leaving group of the substrate.
The catalytic activity of this mutant is severely impaired, but it
maintains a high affinity for substrate and therefore can form
complexes with its targets in the cell that are sufficiently stable
to withstand isolation. It is known that the isolated catalytic
domain of PTP1B is highly promiscuous in vitro, dephospho-
rylating a wide variety of phosphotyrosyl proteins. However,
the application of substrate-trapping mutants has revealed that
PTP1B displays an unexpected degree of substrate selectivity
in a cellular context, recognizing primarily the EGF-R in COS
cells (15). In these experiments, we have used the substrate-
trapping mutant of PTP1B to investigate further elements of
specificity in the action of this phosphatase, particularly with
regard to its antagonism of p210 bcr-abl-induced signalling.
Thus, upon coexpression in COS cells, PTP1B-D181A formed
a stable complex with p210 bcr-abl but not v-Abl, despite the
fact that the latter was expressed abundantly and was tyrosine
phosphorylated. Furthermore, we have shown that the inter-
action between p210 bcr-abl and PTP1B-D181A blocked by
.90% the association of the PTK with Grb2, suggesting that
Y177 in p210 bcr-abl is one of the targets of PTP1B. Disrup-
tion of the interaction with Grb2 is the most likely mechanism
of inhibition of p210 bcr-abl-induced activation of an AP-1/ets
reporter by wild-type and substrate-trapping mutant forms of
PTP1B. Therefore, the selectivity observed in the upregulation
of PTP1B levels in response to expression of p210 bcr-abl is
VOL. 18, 1998 ANTAGONISM OF p210 bcr-abl SIGNALLING BY PTP1B 2973
 o
n
 D
ecem
ber 18, 2013 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
reflected in the selectivity of PTP1B in antagonizing p210 bcr-
abl-induced signalling.
Although these data are consistent with a function of PTP1B
as an antagonist of p210 bcr-abl signalling in vivo, it remains to
be established whether the effects of the PTP are sufficient to
abrogate the transforming potential of this oncoprotein PTK.
In this respect, it is interesting that CML is characterized by a
biphasic disease progression. The indolent chronic phase,
where the only detectable abnormality is the Ph chromosome,
is a semitransformed state that is difficult to distinguish from
normal hematopoiesis and is manifested by an increase in
mature myeloid cells. The disease then progresses to an ag-
gressive phase termed blast crisis, where myeloid cells fail to
differentiate. This phase is characterized by multiple chromo-
somal abnormalities resulting in a truly transformed state that
is reminiscent of acute leukemia (7). Our data suggest the
intriguing possibility that PTP1B may function to suppress
some of the signalling effects of p210 bcr-abl in the chronic
phase of the disease, and such suppression may be lost in the
multiple secondary mutations that accompany blast crisis.
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